US11896558B2

Use of an RXR agonist and taxanes in treating Her2+ cancers

University of Texas System

Abstract

The present specification provides improved methods of treating Her2 + cancers in which an RXR agonist and a taxane are administered to a subject having a Her2 + cancer. Thyroid hormone and other anticancer agents may also be administered. Related compositions and combination are also disclosed.

University: University of Texas System
Assignee: Board Of Regents, The University Of Texas System
Inventor: Martin E. Sanders
Priority date: December 07, 2021
Filing date: December 07, 2022
Grant date: February 13, 2024
Publication date: February 13, 2024
Language: en
PDF source: https://patentimages.storage.googleapis.com/c5/c7/2b/57abebde114129/US11896558.pdf
Metadata fetched: August 29, 2026 00:32